IP Verse

Therapeutic And Diagnostic Methods For Cancer - EP3294770

The patent EP3294770 was granted to F Hoffmann LA Roche on Mar 20, 2024. The application was originally filed on May 12, 2016 under application number EP16724821A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3294770

F HOFFMANN LA ROCHE
Application Number
EP16724821A
Filing Date
May 12, 2016
Status
Patent Maintained As Amended
Feb 16, 2024
Grant Date
Mar 20, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GLAXOSMITHKLINEJul 7, 2021CHIAPPINELLIADMISSIBLE
MERCK PATENTJul 7, 2021-ADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2014151006
INTERNATIONAL-SEARCH-REPORTWO2014197369
OPPOSITIONWO2014151006
OPPOSITIONWO2015036499
OPPOSITIONWO2016034718
OPPOSITIONWO2016183326

Non-Patent Literature (NPL) Citations (18) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- "A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)", History of Changes for Study: NCT02087423, (20150417), URL: https://clinicaltrials.gov/ct2/history/NCT02087423?V_12=View#StudyPageTop, XP055828943
OPPOSITION- Anonymous, "A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)", ClinicalTrials.gov Identifier: NCT02087423, (20150420), pages 1 - 26, XP055828943
OPPOSITION- "A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced Small Cell Lung Cancer - "BIRCH"", History of Changes for Study: NCT02031458, (20150505), URL: https://clinicaltrials.gov/ct2/history/NCT02031458?V_56=View#StudyPageTop, XP055828941
OPPOSITION- CREELAN, "Update on Immune Checkpoint Inhibitors in Lung Cancer", Cancer Control, (20140101), vol. 21, no. 1, pages 80 - 89, XP055203442
OPPOSITION- SORIA et al., "Clinical activity, safety and biomarkers of PD-L1 blockade in non-small cell lung cancer (NSCLC): additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)", European Journal of Cancer, (20130000), vol. 49, no. 2, pages S759 - S892, XP055934864
OPPOSITION- Johnson Douglas B., Rioth Matthew J., Horn Leora, "Immune Checkpoint Inhibitors in NSCLC", Current Treatment Options in Oncology, (20140806), vol. 15, pages 658 - 669, XP055257614
OPPOSITION- JOHNSON et al., "Immune Checkpoint Inhibitors in NSCLC", Current Treatment Options in Oncology, (20140806), vol. 15, doi:10.1007/s11864-014-0305-5, pages 658 - 669, XP055257614
OPPOSITION- Laiho Jutta E., Oikarinen Maarit, Richardson Sarah J., Frisk Gun, Nyalwidhe Julius, Burch Tanya C., Morris Margaret A., Oikarinen Sami, Pugliese Alberto, Dotta Francesco, Campbell-Thompson Martha, Nadler Jerry, Morgan Noel G., Hyöty Heikki, "Relative sensitivity of immunohistochemistry, multiple reaction monitoring mass spectrometry, in situ hybridization and PCR to detect Coxsackievirus B1 in A549 cells", Journal of Clinical Virology, (20160000), vol. 77, pages 21 - 28, XP029460268
OPPOSITION- Tsao Ming Sound, Kerr Keith M., Kockx Mark, Beasley Mary-Beth, Borczuk Alain C., Botling Johan, Bubendorf Lukas, Chirieac Lucian, Chen Gang, Chou Teh-Ying, Chung Jin-Haeng, Dacic Sanja, Lantuejoul Sylvie, Mino-Kenudson Mari, Moreira Andre L., Nicholson Andrew G., Noguchi Masayuki, Pelosi Giuseppe, Poleri Claudia, Russell Prudence A., Sauter Jennifer, Thunnissen Erik, Wistuba Ignacio, Yu Hui, Wynes Murry W., Pintilie Melania, Yatabe Yasushi, Hirsch Fred R., "PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project", Journal of Thoracic Oncology, (20180522), vol. 13, no. 9, pages 1302 - 1311, XP055934859
OPPOSITION- GARON et al., "Correlation of clinical activity of pembrolizumab (MK - 3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in ?50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation population", European Journal of Cancer, (20141119), vol. 50, no. 6, pages 44 - 45, XP055828932
OPPOSITION- Garon Edward B., Rizvi Naiyer A., Hui Rina, Leighl Natasha, Balmanoukian Ani S., Eder Joseph Paul, Patnaik Amita, Aggarwal Charu, Gubens Matthew, Horn Leora, Carcereny Enric, Ahn Myung-Ju, Felip Enriqueta, Lee Jong-Seok, Hellmann Matthew D., Hamid Omid, Goldman Jonathan W., Soria Jean-Charles, Dolled-Filhart Marisa, Rutledge Ruth Z., Zhang Jin, Lunceford Jared K., Rangwala Reshma, Lubiniecki Gregory M., Roach Charlotte, Emancipator Kenneth, Gandhi Leena, "Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer", N Engl J Med, (20150419), vol. 372, pages 2018 - 2028, XP055306209
OPPOSITION- GARON et al., "Pembrolizumab for the Treatment of Non-Small- Cell Lung Cancer", The New England Journal of Medicine, vol. 372, no. 21, doi:10.1056/NEJMoa1501824, (20150419), pages 2018 - 2028, XP055306209
OPPOSITION- Buqué Aitziber, Bloy Norma, Aranda Fernando, Castoldi Francesca, Eggermont Alexander, Cremer Isabelle, Fridman Wolf Hervé, Fucikova Jitka, Galon Jérôme, Marabelle Aurélien, Spisek Radek, Tartour Eric, Zitvogel Laurence, Kroemer Guido, Galluzzi Lorenzo, "Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications", OncoImmunology, (20150427), vol. 4, no. 4, pages 1 - 16, XP055540479
OPPOSITION- Gray J.E., Garassino M.C., Vansteenkiste J.F., Ballas M., Jayawardene D., Stockman P.K., Powderly J.D., Rizvi N., "Phase 2, Open-Label, International, Non-Comparative Study of MEDI4736 in Patients with Locally Advanced or Metastatic, Pd-L1 +, Stage 3B-4 Nsclc Who Have Received ≥2 Prior Systemic Treatment Regimens (ATLANTIC)", Annals of Oncology, (20150000), vol. 26, no. 1, pages i29 - i44, XP055934840
OPPOSITION- Gettinger Scott, Herbst Roy S, "B7-H1/PD-1 blockade therapy in non-small cell lung cancer current status and future direction", The cancer journal (Sudbury, Mass.), (20140000), vol. 20, pages 281 - 289, XP055934829
OPPOSITION- PATEL et al., "PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy", Molecular Cancer Therapeutics, (20150218), vol. 14, no. 4, doi:10.1158/1535-7163.MCT-14-0983, pages 847 - 856, XP055567991
OPPOSITION- Brahmer Julie, Balmanoukian Ani, Goldberg Sarah, Ou Sai-Hong, Blake-Haskins Andrew, Karakunnel Joyson, Stockman Paul, Rizvi Naiyer, Antonia Scott, "Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)", Journal for ImmunoTherapy of Cancer, (20141106), vol. 2, no. 3, page P179, XP021202443
OPPOSITION- Sinn Hans-Peter, Schneeweiss Andreas, Keller Marius, Schlombs Kornelia, Laible Mark, Seitz Julia, Lakis Sotirios, Veltrup Elke, Altevogt Peter, Eidt Sebastian, Wirtz Ralph M., Marmé Frederik, "Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer", BMC Cancer, (20170000), vol. 17, page 124, XP055656289

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents